Brief: Exelixis And Arcus Biosciences Announce Clinical Trial Collaboration To Evaluate Zanzalintinib In Combination With Ab521
04/12/2023 15:18
Dec 4 (Reuters) - Exelixis Inc EXEL.O :
* EXELIXIS AND ARCUS BIOSCIENCES ANNOUNCE CLINICAL TRIAL
COLLABORATION TO EVALUATE ZANZALINTINIB IN COMBINATION WITH
AB521 IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
* ARCUS BIOSCIENCES INC - PHASE 1B/2 CLINICAL TRIAL EXPECTED
TO
BEGIN ENROLLING PATIENTS BEFORE YEAR-END 2023
Source text for Eikon: ID:nBw7BW9zLa
Further company coverage: EXEL.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Arcus Biosciences
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Arcus Biosciences tumbles on $250 mln share sale
Brief: Arcus Biosciences Announces Pricing Of $250 Million Public Offering Of Common Stock
Arcus Biosciences drops after starting stock offering